Ixekizumab 80mg subcutaneous injection What Ixekizumab is used for: It is a humanized interleukin-17A antagonist indicated for the treatment of: Patients aged 6 years or older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Adults with active psoriatic arthritis. Adults with active ankylosing spondylitis Do not take Ixekizumab if: Hypersensitivity to Ixekizumab Important active infections (like tuberculosis: serious infectious disease that mainly affects your lungs) Warnings & Precautions: Talk to your doctor or pharmacist If you develop tuberculosis If you have inflammatory bowel disease (Crohn’s disease or ulcerative colitis) If you develop an infection or are being treated for infection If you received a vaccine while taking the medication Possible Side Effects: Injection site reaction (itching, redness) Nausea Upper respiratory tract infections like swelling of the nasal passages and the back of the throat Other medicines and Ixekizumab Tell your doctor or pharmacist about all medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements. Monitor all drugs that are CYP450 substrates because of increased risk of side effects. Monitor mainly narrow therapeutic index drugs like: warfarin, cyclosporine, phenytoin, gentamicin How to take Ixekizumab: Plaque Psoriasis Adult Recommended dose is 160 mg (two 80 mg injections) at Week 0 followed by 80 mg at Weeks 2, 4, 6, 8, 10, and 12, then 80 mg every 4 weeks. Pediatric For patients weighing greater than 50 kg: recommended dose is 160 mg at Week 0, followed by 80 mg every 4 weeks. For patients weighing 25-50 kg: recommended dose is 80 mg at Week 0, followed by 40 mg every 4 weeks. For patients weighing less than 25 kg: recommended dose is 40 mg at Week 0, followed by 20 mg every 4 weeks. Psoriatic Arthritis Recommended dose is 160 mg by subcutaneous injection (two 80 mg injections) at Week 0, followed by 80 mg every 4 weeks. Ankylosing Spondylitis Recommended dose is 160 mg by subcutaneous injection (two 80 mg injections) at Week 0, followed by 80 mg every 4 weeks. How To Use: It is administered subcutaneously (injection under the skin) Before injection, remove Ixekizumab from the refrigerator and allow it to reach room temperature (30 minutes) without removing the needle cap. Inspect visually for particulate matter and discoloration prior to administration. It is a clear and colorless to slightly yellow solution. Do not use if the liquid contains visible particles, is discolored or cloudy (other than clear and colorless to slightly yellow). Administer each injection at a different anatomic location (such as upper arms, thighs or any quadrant of abdomen) than the previous injection, and not into areas where the skin is tender, bruised, erythematous, indurated or affected by psoriasis How to store Ixekizumab: Keep this medicine out of the sight and reach of children. Ixekizumab must be protected from light until use. Store refrigerated at 2°C to 8°C (36°F to 46°F). If needed, you may store Ixekizumab at room temperature up to 30°C (86°F) for up to 5 days in the original carton to protect from light. Once Ixekizumab has been stored at room temperature, do not return to the refrigerator and discard, if unused, within 5 days. For the 2 or 3 autoinjector pack, remove a single autoinjector at a time leaving the remaining autoinjector(s) in the original carton in the refrigerator. Do not use Ixekizumab if it has been frozen. Do not shake. Discard the Ixekizumab single-dose autoinjector or syringe after use in a puncture-resistant container.